Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Inc. is a biopharmaceutical company dedicated to pioneering the development of innovative therapies for genetically defined diseases. The core focus of Agios is to leverage the science of cellular metabolism to develop transformative treatments for patients. Key areas of impact include hematological malignancies and rare genetic diseases, where the company has made significant strides in understanding and targeting the metabolic pathways that drive disease. Agios Pharmaceuticals conducts extensive research to identify and advance drug candidates, optimizing their potential impact on improving patient outcomes. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company operates within the burgeoning biotech and healthcare sectors, contributing to revolutionary advances in medical treatments. Agios’ commitment to research excellence and its focus on unmet medical needs underscore its significance in the biotechnology market, positioning it as a notable player in the field of next-generation therapeutic development.